In patients with type 2 diabetes and chronic kidney disease, the medication semaglutide is associated with a lower chance of developing kidney failure and other kidney-related complications, even...
Mechanism
Synthesis from 3 studies
Semaglutide works directly on the kidneys to reduce swelling, scarring, and damage from harmful molecules, helping them filter blood better. This happens even if the person doesn’t lose weight, because the drug acts on the kidneys themselves, not just through weight changes.
Most probable mechanism
Semaglutide binds to receptors in the kidneys, which turns down signals that cause swelling, scarring, and damage from harmful molecules. This helps the kidneys filter blood better and slows down damage, even if the person doesn't lose weight.
Semaglutide binds to GLP-1 receptors on renal tubular epithelial cells and podocytes
Receptor binding activates intracellular cAMP/PKA signaling pathways
PKA signaling suppresses NF-κB and NLRP3 inflammasome activation, reducing production of pro-inflammatory cytokines such as IL-1β and TNF-α
cAMP/PKA signaling inhibits TGF-β/Smad and MAPK pathways, decreasing extracellular matrix deposition and renal fibrosis
Oxidative stress is reduced through upregulation of antioxidant enzymes and inhibition of NADPH oxidase
Improved endothelial function and reduced glomerular hyperfiltration occur via modulation of tubuloglomerular feedback and nitric oxide production
Evidence from Studies
Supporting (3)
Community contributions welcome
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.